A new trading day began on Monday, with Viking Therapeutics Inc (NASDAQ: VKTX) stock price down -5.92% from the previous day of trading, before settling in for the closing price of $22.62. VKTX’s price has ranged from $21.53 to $81.86 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -57.96%. With a float of $108.95 million, this company’s outstanding shares have now reached $111.57 million.
The extent of productivity of a business whose workforce counts for 36 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Viking Therapeutics Inc (VKTX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Viking Therapeutics Inc is 2.94%, while institutional ownership is 73.47%. The most recent insider transaction that took place on Mar 31 ’25, was worth 29,943. In this transaction Director of this company bought 1,240 shares at a rate of $24.15, taking the stock ownership to the 1,240 shares. Before that another transaction happened on Jan 06 ’25, when Company’s President & CEO sold 194,490 for $42.75, making the entire transaction worth $8,313,601. This insider now owns 2,366,570 shares in total.
Viking Therapeutics Inc (VKTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -57.96% per share during the next fiscal year.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Here are Viking Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 33.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.01, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -2.16 in one year’s time.
Technical Analysis of Viking Therapeutics Inc (VKTX)
The latest stats from [Viking Therapeutics Inc, VKTX] show that its last 5-days average volume of 4.97 million was superior to 4.41 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 13.78%. Additionally, its Average True Range was 2.08.
During the past 100 days, Viking Therapeutics Inc’s (VKTX) raw stochastic average was set at 2.08%, which indicates a significant decrease from 9.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.59% in the past 14 days, which was lower than the 77.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.13, while its 200-day Moving Average is $48.86. Now, the first resistance to watch is $22.76. This is followed by the second major resistance level at $24.25. The third major resistance level sits at $25.49. If the price goes on to break the first support level at $20.03, it is likely to go to the next support level at $18.79. The third support level lies at $17.30 if the price breaches the second support level.
Viking Therapeutics Inc (NASDAQ: VKTX) Key Stats
With a market capitalization of 2.39 billion, the company has a total of 112,248K Shares Outstanding. Currently, annual sales are 0 K while annual income is -109,960 K. The company’s previous quarter sales were 0 K while its latest quarter income was -35,420 K.
